TAK-921

Antibody–drug conjugate

Also known as IBI343

Phase 1/2Mechanism not established
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT07066098 · Innovent Biologics (Suzhou) Co. Ltd.
2025-07-17 – 2028-06-30 · Pancreatic Cancer
What this study did
NCT06238843 · Innovent Biologics (Suzhou) Co. Ltd.
2024-06-30 – 2027-12-31 · Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (5)
Other / comorbidity
NCT07483567 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-17 – 2031-06-30 · CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07415525 · Zhejiang University
2026-02-01 – 2030-12-31 · Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma
What this study did
NCT07483554 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-20 – 2028-03-31 · CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
What this study did
NCT06770439 · Zhejiang University
2025-04-18 – 2028-01 · Advanced Pancreatic Cancers
What this study did
NCT06321913 · Harbin Medical University
2024-03-15 – 2025-12-31 · Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 1/2 (2)
Gastric Cancer
NCT07025889 · Ruijin Hospital
2025-06-02 – 2028-06 · Gastric Cancer
What this study did
Other / comorbidity
NCT07692750 · Zhejiang Cancer Hospital
2025-04-30 – 2027-12-31 · Advanced Pancreatic Cancer
What this study did
Phase 1 (1)
Other / comorbidity
NCT05458219 · Innovent Biologics (Suzhou) Co. Ltd.
2022-10-26 – 2027-12-31 · Locally Advanced Unresectable or Metastatic Solid Tumors
What this study did

Competitive landscape

This drug's own stage for Gastric Cancer: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
TAK-921: this drugPhase 1/2Antibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Reliable signal
NCT01170663: Overall Survival Time (OS) (Randomization up to 27.5 months): Ramucirumab (IMC-1211B) Plus Paclitaxel 9.6 months (95% CI 8.5 to 10.8) | Placebo Plus Paclitaxel 7.4 months (95% CI 6.3 to 8.4)
NCT00917384: Overall Survival (OS) (Randomization up to 28 months post-randomization): IMC-1121B (Ramucirumab) 5.2 months (95% CI 4.4 to 5.7) | Placebo 3.8 months (95% CI 2.8 to 4.7)
TislelizumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabApprovedMultispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ASP2138Phase 3Multispecific antibodyClaudin 18.2 x CD3not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 3Small moleculeProstaglandin E2 receptor 4 (EP4)Reliable signal
NCT06256328: ONO-4578-08 study (NCT06256328): median PFS 9.0 months (ONO-4578 + nivolumab + chemotherapy) vs 6.9 months (placebo + nivolumab + chemotherapy); HR 0.67, 90% CI 0.48-0.92, P=0.040.
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signal
NCT04950322: Primary endpoint, overall survival vs placebo plus CAPOX: median 16.8 vs 10.4 months (HR 0.53) in PD-L1 CPS >=5 and 15.8 vs 11.2 months (HR 0.66) in the ITT set (JCO, 2026-09-24).
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Sonesitatug VedotinPhase 3Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
agenT-797Phase 2Cell therapyInvariant TCR / NKG2D ligands (tumor cell recognition), no single defined myeloma antigennot yet gradedNo reviewed efficacy summary in this indication
GivastomigPhase 2Multispecific antibodyClaudin 18.2 (CLDN18.2) x 4-1BBnot yet gradedNo reviewed efficacy summary in this indication
SHR-A1904Phase 2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
ASP546C
Phase 1/2(overall)
Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow TAK-921 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06238843 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 2Advanced Pancreatic CancersRecruiting
Est. primary completion 2027-01 · NCT06770439 · CT.gov ↗
What to watch
June 2027 (3)
Phase 1Locally Advanced Unresectable or Metastatic Solid TumorsRecruiting
Est. primary completion 2027-06-30 · NCT05458219 · CT.gov ↗
What to watch
Phase 1/2Advanced Pancreatic CancerRecruiting
Est. primary completion 2027-06-30 · NCT07692750 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerRecruiting
Est. primary completion 2027-06-30 · NCT07066098 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-07 · NCT07025889 · CT.gov ↗
What to watch
2028 (2)
March 2028 (1)
Phase 2CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-03-31 · NCT07483554 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Pancreatic Cancer, Borderline Resectable Pancreatic AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07415525 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 2CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07483567 · CT.gov ↗
What to watch

See the full readout calendar ↗